Overview

This trial is active, not recruiting.

Condition liver cancer
Treatment iressa
Phase phase 2
Target EGFR
Sponsor Sidney Kimmel Comprehensive Cancer Center
Collaborator Singapore Cancer Syndicate.
Start date December 2005
End date December 2012
Trial size 40 participants
Trial identifier NCT00282100, JS0414, NCT00228501

Summary

This research is being done to find how soon the liver cancer may come back and whether proteins or genes in tumor, blood or urine can give us clues of early recurrence.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose prevention

Primary Outcomes

Measure
To study the changes of selected genetic or protein markers through the treatment and find out whether some of them can be potential biomarkers for disease relapse.
time frame:

Secondary Outcomes

Measure
To evaluate the effect of gefitinib as an adjuvant therapy on recurrence free survival in patients with resectable hepatocellular carcinoma; to evaluate the treatment toxities of genifitib.
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria

    Exclusion Criteria

      Additional Information

      Principal investigator Alex Chang, M.D.
      Description Hepatocellular carcinoma (HCC) is one of the most common cancers in the world1. HCC risk increases drastically in patients with chronic hepatitis B infection, hepatitis C infection or liver cirrhosis. HCC is very prevalent in our region due to endemic hepatitis B infection and increasing incidence of hepatitis C. Patients with HCC have very poor prognosis because HCC tumors are usually non-symptomatic. Most patients will not be diagnosed until the disease has reached an advanced stage. Chemotherapy may offer palliative benefit to some patients with advanced HCC but has not been shown to prolong survival in these patients. HCC patients are in need for innovative and targeted therapies. Therefore, we propose to study gefitinib as an adjuvant therapy in patients with resected HCC. Gefitinib blocks the function of epidermal growth factor receptor which is a key factor in stimulating liver cancer growth. In mice, gefitinib has been shown to reduce the size of liver cancer. It also had anti tumor activity in patients with various cancers including HCC. Gefitinib can relieve disease-related symptoms in these patients. Overall, gefitinib is a very well tolerated treatment and is suitable for long-term use. At the time of diagnosis and surgical evaluation, patients with resectable hepatocellular carcinoma will be asked to participate in this study.Patients will be registered after consent form is obtained. Patient is asked to donate tumor tissues, urine and blood samples.Tumorand normal specimens are collected at the time of surgery. After patient recovers from surgery (4-6 weeks) and fullfills the eligiblity, patient will receive gefitinib 250 mg p.o. daily for 6 months. Patient will remain on study till completion of treatment. The following are conditions when your study doctor will remove you from the study or stop the therapy: 1. Interruption of treatment for 4 consecutive weeks due to side effects, which do not resolve. 2. withdraw of consent by patient. ii. Your disease becomes worse. iii. New information that gefitinib treatment is harmful to patients has become available. Patient will be evaluated at one month, 3 months and 6 months on gefitinib. After that, evaluate patient at least every 3 months for first 2 years, then every 6 months for next 3 years, then yearly afterwards. Draw blood and store sera and urine at the same interval until relapse and/or death. Conduct correlative studies of urine, serum and tumor tissue with clinical outcome.
      Trial information was received from ClinicalTrials.gov and was last updated in December 2008.
      Information provided to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center.